Background: Refractory angina pectoris (AP) significantly impairs quality of life in patients with chronic coronary syndrome. Several minimally invasive methods (coronary sinus reducer, cell therapy, laser or shockwave revascularization, and spinal cord stimulation) or non-invasive methods (external counterpulzation) have been studied. However, their routine clinical use has not been widely implemented. Surgical or endoscopic sympathectomy is feasible for permanently relieving angina, but is often contraindicated due to the extent of complications associated with it. Neuromodulation by anaesthetic blockade of the left-sided stellate ganglion (SG) has been shown to relieve angina for days or weeks. To provide a long-term anti-anginal effect, novel pharmacological (phenol-based) or radiofrequency ablation techniques have been individually used to permanently destroy sympathetic pathways.

Case Summary: We describe a first-in-man use of stereotactic radiosurgical SG ablation using a linear accelerator (CyberKnife) in a heart failure patient after myocardial infarction with chronic refractory AP. Repeated anaesthetic SG blockade in this patient resulted in a significant, but only short-term, clinical improvement. The left, and subsequently the right, SG was ablated by targeted irradiation. During the 1-year follow-up, the patient remained without angina. We did not observe any clinically relevant early or late complications. Atrial fibrillation that developed 2 months after the second procedure was deemed to be associated with a natural progression of co-existing heart failure.

Discussion: We conclude that stereotactic radiosurgical SG ablation has the potential to become a minimally invasive and low-risk procedure to treat refractory angina patients. However, this procedure needs to be evaluated in larger patient populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422337PMC
http://dx.doi.org/10.1093/ehjcr/ytab184DOI Listing

Publication Analysis

Top Keywords

refractory angina
12
stereotactic radiosurgical
12
chronic refractory
8
angina pectoris
8
stellate ganglion
8
minimally invasive
8
anaesthetic blockade
8
radiosurgical ablation
8
angina
6
pectoris treated
4

Similar Publications

Bridging the Gender Gap in Cardiovascular Medicine: Addressing Drug Intolerances and Personalized Care for Women with Angina/Ischemia with Non-Obstructive Coronary Artery Disease.

J Cardiovasc Dev Dis

November 2024

Robert Bosch Krankenhaus, Department of Cardiology and Angiology, Auerbachstr. 110, 70376 Stuttgart, Germany.

Gender medicine has increasingly underscored the necessity of addressing sex-based differences in disease prevalence and management, particularly within cardiovascular conditions and drug intolerance. Women often present cardiovascular diseases distinctively from men, with a higher prevalence of non-obstructive coronary artery disease and varied ischemic manifestations, such as coronary microvascular dysfunction and epicardial or microvascular coronary spasm. This disparity is further exacerbated by elevated drug intolerance rates among women, influenced by hormonal, genetic, and psychosocial factors.

View Article and Find Full Text PDF

Background: The coronary sinus reducer (CSR) is a therapeutic option for patients with coronary artery disease who are not eligible for further revascularization and experience refractory angina. Cardiac resynchronization therapy (CRT) improves symptoms and prognosis in heart failure with reduced ejection fraction, but the presence of a CSR may complicate left ventricular lead placement. Only four cases have been reported so far in this context.

View Article and Find Full Text PDF

Procedural factors influencing successful coronary sinus reducer implantation for refractory angina: A single-centre experience.

Cardiovasc Revasc Med

December 2024

Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, Chelsea, London SW3 6NP, UK; National Heart and Lung Institute, Imperial College London, UK. Electronic address:

Background: Coronary sinus reducer (CSR) implantation is emerging as a novel effective percutaneous therapy for patients with refractory angina. Limited data exists examining the factors influencing successful CSR implantation. As CSR implantation becomes more widely adopted, a greater understanding of the procedural challenges which operators encounter is required.

View Article and Find Full Text PDF

New Directions in Coronary Revascularization for Refractory Angina: Gene Therapy and the Lizard Heart.

Semin Thorac Cardiovasc Surg

December 2024

Department of Surgery, Division of Cardiac Surgery, The Ohio State University, Columbus, Ohio. Electronic address:

Refractory angina is a debilitating disease with limited therapeutic options that is primarily caused by microvascular dysfunction and desertification. Towards addressing this unmet need, microvascular revascularization therapy has progressively evolved from the lizard heart inspired transmyocardial revascularization to precisely inducing vascular endothelial growth factor with gene therapy. Gene therapy with adenoviral vehicles or naked modified ribonucleic acid is safe and shows early signs of clinical promise but has not yet been proven effective due to gaps in optimization.

View Article and Find Full Text PDF

[Current state of algology - pain medicine - in the Russian Federation].

Zh Vopr Neirokhir Im N N Burdenko

December 2024

JSC «K+31», Moscow, Russia.

Objective: To analyze the structure of care for patients with pain syndromes in the Russian Federation and possible improvement of these approaches.

Material And Methods: A detailed questionnaire was sent to 60 pain clinics. We received responses from 40 hospitals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!